AbBC Therapies

Executive Summary

AbBC Therapies is a private biotechnology company headquartered in Cambridge, MA, focused on developing next-generation targeted immunotherapies. The company's core technology is the Targeted Granzyme B Immunotherapy (TGI) platform, which fuses tumor-targeting antibodies with human Granzyme B, a potent serine protease. This approach enables direct delivery of cytotoxic activity to cancer cells while sparing healthy tissues, potentially offering improved safety and efficacy over conventional antibody-drug conjugates or checkpoint inhibitors. Founded in 2020, AbBC has advanced its lead candidate, TGI-101, into Phase 1 clinical evaluation for solid tumors, leveraging a novel mechanism that induces apoptosis independent of the immune system. The platform's versatility allows for rapid engineering of new candidates across multiple cancer types, and the company is also exploring applications in autoimmune diseases. Despite being at an early stage, AbBC's differentiated approach addresses key limitations of current immunotherapies, such as resistance and off-target toxicity. The company's progress is closely watched by biotech investors, as successful proof-of-concept in humans could unlock significant value through partnerships or further financing. With a lean structure and a focus on precision oncology, AbBC Therapies represents a high-risk, high-reward opportunity in the evolving landscape of biologic therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data for lead candidate TGI-101 in solid tumors60% success
• Q4 2026FDA clearance of IND for second program TGI-201 in hematologic malignancies70% success
• Q2 2026Preclinical proof-of-concept data for bispecific TGI platform at a major medical conference80% success